Learn how reference standards play a key role in increasing and confirming the accuracy of diagnostic testing, thus bringing us closer to precision medicine and targeted therapy.
HAP1 cell lines are a popular choice to validate a range of research experiments, but if you've never used them before, you want to be sure they are right for you.
Liquid biopsy is fast becoming a realistic clinical diagnostic tool, capable of profiling the molecular makeup of a tumor that aids in choosing the right drug and in monitoring treatment response. Studies for its use in early cancer detection are already underway with promising results.
After all the hard work of editing your cell line, you want to have confidence in your new research model. So, how do you verify your cell line is what you expect it to be? Could a heterogeneous cell population be obscuring your editing effects? Is observed phenotype being caused by the targeted gene edit, or unintended off-target effects? Here we discus ways to add supporting data to validate your gene-engineering projects.
Acute Myeloid Leukaemia (AML) is a group of blood cancer malignancies that originate from the uncontrolled proliferation of blast cells in the bone marrow and circulating blood1. AML is a relatively rare disorder - representing less than 1% of total cancer cases.
A major study has been undertaken to gain a better understanding of thousands of mutations in the BRCA1 gene - a key gene in breast and ovarian cancers.
The only self-delivering siRNA for difficult-to-transfect cells carries a functional guarantee.
CRISPRテクノロジーは、遺伝子と分子パスウェイをより明確に調べることを可能にしました。どのように、ノックアウト細胞株を、遺伝子レスキューと疾患変異モデルとともに、または独立した細胞モデルとして使用して、研究を検証し、研究成果を拡張できるかを説明しています。
See from a real example how Horizon's reference standards can be used to validate a new NGS assay technology.
Top ten recommendations to validate your NGS assay.